Abstract
Hepatitis B virus is one of the leading causes of chronic liver diseases such as hepatocellular carcinoma and cirrhosis. The number of HBV-infected people worldwide is estimated at more than 400 million, and the complications associated with the infection have become a serious global health problem. Evaluating liver fibrosis is crucial for making therapeutic decisions and predicting outcomes in patients with chronic hepatitis B.